Literature DB >> 270702

Detection of antibody to autologous human leukemia cells by immune adherence assays.

T J Garrett, T Takahashi, B D Clarkson, L J Old.   

Abstract

The sera of 21 adult patients with acute leukemia were studied for the presence of antibody reacting with surface antigens of autologous leukemia cells. Sequential serum samples were obtained from patients and were tested on cryopreserved leukemia cells in immune adherence assays. Three patients showed autologous serum reactivity and the serum of one of them was analyzed in detail. This antibody reacted with autologous acute lymphocytic leukemia cells but not with autologous cells obtained from peripheral blood, bone marrow, or spleen during clinical remission. In absorption tests, the antigen could not be detected on normal autologous or allogeneic blood lymphocytes, lymphoblastoid lines of T- or B-cell origin, or cells infected with simian sarcoma virus, baboon C-type virus, or Mason-Pfizer virus. Leukemia cells from two other patients with acute lymphocytic leukemia and one patient with acute nonlymphocytic leukemia absorbed specific reactivity. These studies indicate that certain acute leukemia cells express a common antigen that elicits a humoral immune response in the autologous host.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 270702      PMCID： PMC431991          DOI： 10.1073/pnas.74.10.4587

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  9 in total

1.  Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells.

Authors:  L J Old; E A Boyse; H F Oettgen; E D Harven; G Geering; B Williamson; P Clifford
Journal:  Proc Natl Acad Sci U S A       Date:  1966-12       Impact factor: 11.205

2.  Oncogenic RNA viruses.

Authors:  R C Gallo; G J Todaro
Journal:  Semin Oncol       Date:  1976-03       Impact factor: 4.929

3.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

Review 4.  Leukaemia antigens and immunity in man.

Authors:  R Harris
Journal:  Nature       Date:  1973-01-12       Impact factor: 49.962

5.  Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics.

Authors:  H Shiku; T Takahashi; L A Resnick; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

6.  Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

Authors:  T E Carey; T Takahashi; L A Resnick; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

7.  Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro.

Authors:  L J Old; E Stockert; E A Boyse; J H Kim
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

8.  Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.

Authors:  H Shiku; T Takahashi; H F Oettgen
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

9.  Epstein-barr virus-negative human malignant T-cell lines.

Authors:  J Kaplan; T C Shope; W D Peterson
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307
  9 in total
  14 in total

1.  Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8).

Authors:  Catharina Steentoft; Katrine T Schjoldager; Emiliano Cló; Ulla Mandel; Steven B Levery; Johannes W Pedersen; Knud Jensen; Ola Blixt; Henrik Clausen
Journal:  Glycoconj J       Date:  2010-08-19       Impact factor: 2.916

2.  Autologous typing: a tedious but orthodox approach for defining human tumor antigens with clarity.

Authors:  Hiroshi Shiku; Toshitada Takahashi
Journal:  Cancer Immun       Date:  2012-05-01

3.  Serological analysis of cell surface antigens of malignant human brain tumors.

Authors:  M Pfreundschuh; H Shiku; T Takahashi; R Ueda; J Ransohoff; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

4.  Autologous and allogeneic typing of human leukemia cells: definition of surface antigens restricted to lymphocytic leukemia cells.

Authors:  K Naito; H Yamaguchi; K Horibe; H Shiku; T Takahashi; S Suzuki; K Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

5.  Immune complexes and circulating antibodies against autologous leukaemic cells in patients with acute leukaemias.

Authors:  M Bertini; G Galetto; P M Comoglio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

6.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.

Authors:  A Knuth; B Danowski; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

7.  Natural antibody to a human bladder carcinoma cell line.

Authors:  H B Grossman
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

8.  Effect of neuraminidase treatment on serum reactivity to autologous leukemic blast cells.

Authors:  M Pfreundschuh; B Dörken; W Brandeis; W Hunstein; P Wernet
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Comparison of [3H]glucosamine-labeled glycoproteins from human renal cancer and normal kidney epithelial cell cultures by two-dimensional polyacrylamide gel electrophoresis.

Authors:  S Ogata; R Ueda; K O Lloyd
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

10.  Cell surface antigens of human renal cancer defined by autologous typing.

Authors:  R Ueda; H Shiku; M Pfreundschuh; T Takahashi; L T Li; W F Whitmore; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.